CN103830481A - 治疗小儿反复呼吸道感染的药物 - Google Patents
治疗小儿反复呼吸道感染的药物 Download PDFInfo
- Publication number
- CN103830481A CN103830481A CN201410114442.9A CN201410114442A CN103830481A CN 103830481 A CN103830481 A CN 103830481A CN 201410114442 A CN201410114442 A CN 201410114442A CN 103830481 A CN103830481 A CN 103830481A
- Authority
- CN
- China
- Prior art keywords
- medicine
- children
- respiratory tract
- tract infection
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 229940079593 drug Drugs 0.000 title description 7
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 7
- 230000036737 immune function Effects 0.000 abstract description 4
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 229940099472 immunoglobulin a Drugs 0.000 abstract 2
- 229940027941 immunoglobulin g Drugs 0.000 abstract 2
- 244000080767 Areca catechu Species 0.000 abstract 1
- 235000006226 Areca catechu Nutrition 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 241001180873 Saposhnikovia divaricata Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 210000000952 spleen Anatomy 0.000 description 25
- 210000004072 lung Anatomy 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 7
- 208000008454 Hyperhidrosis Diseases 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000037315 hyperhidrosis Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000037920 primary disease Diseases 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010039101 Rhinorrhoea Diseases 0.000 description 4
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- DNJFTXKSFAMXQF-UHFFFAOYSA-N Arecaidine Chemical compound CN1CCC=C(C(O)=O)C1 DNJFTXKSFAMXQF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical group C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 244000133098 Echinacea angustifolia Species 0.000 description 2
- 239000010105 Esberitox Substances 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001062009 Indigofera Species 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 108010074506 Transfer Factor Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000014134 echinacea Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010753 nasal discharge Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- -1 phenethyl alcohol glycosides Chemical class 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- ICWHTQRTTHCUHW-IPYPFGDCSA-N 2-[(3s,5r,6r)-6,10-dimethylspiro[4.5]dec-9-en-3-yl]propan-2-ol Chemical compound C[C@@H]1CCC=C(C)[C@]11C[C@@H](C(C)(C)O)CC1 ICWHTQRTTHCUHW-IPYPFGDCSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- ICWHTQRTTHCUHW-UHFFFAOYSA-N Agarospirol Natural products CC1CCC=C(C)C11CC(C(C)(C)O)CC1 ICWHTQRTTHCUHW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- ATDBDSBKYKMRGZ-ZDUSSCGKSA-N Cimifugin Chemical compound O1C(CO)=CC(=O)C2=C1C=C1O[C@H](C(C)(C)O)CC1=C2OC ATDBDSBKYKMRGZ-ZDUSSCGKSA-N 0.000 description 1
- ATDBDSBKYKMRGZ-UHFFFAOYSA-N Cimifugin Natural products O1C(CO)=CC(=O)C2=C1C=C1OC(C(C)(C)O)CC1=C2OC ATDBDSBKYKMRGZ-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- LLKXNMNOHBQSJW-UHFFFAOYSA-N Elemol Natural products CCC(=C)C1CC(C=CC1(C)C)C(C)(C)O LLKXNMNOHBQSJW-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- OFECPTGTEKSUPH-UHFFFAOYSA-N Visamminol Natural products CC1=CC(=O)c2cc3CC(Oc3cc2O1)C(C)(C)O OFECPTGTEKSUPH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- GFJIQNADMLPFOW-UHFFFAOYSA-N cis-Elemol Natural products CC(=C)C1CC(C(C)(C)O)CCC1(C)C=C GFJIQNADMLPFOW-UHFFFAOYSA-N 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- GFJIQNADMLPFOW-VNHYZAJKSA-N elemol Chemical compound CC(=C)[C@@H]1C[C@H](C(C)(C)O)CC[C@@]1(C)C=C GFJIQNADMLPFOW-VNHYZAJKSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940072266 pulmicort Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003521 tetracyclic triterpenoids Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明为治疗小儿反复呼吸道感染的药物,属于中药领域,特点是由黄芪、白术、茯苓、防风、苍术、煅牡蛎、大腹皮和连翘成按一定重量配比制成。能明显改善反复呼吸道感染患儿临床症状,激发患儿自身免疫系统,使IgA,IgG,IgM分泌增加,从而提高患儿机体体液免疫功能。改善患者的免疫力、减少发病次数,用药过程中未见任何不良反应,可长期服用,易于被儿童接受。
Description
技术领域
本发明属于中药领域,特别是一种治疗小儿反复呼吸道感染的中药制剂。
背景技术
小儿反复呼吸道感染简称“复感儿”,是指在单位时间内上、下呼吸道感染反复发作超过规定次数的一种临床综合征。中医学依据其发病临床症状把本病归属于“体虚感冒”、“咳嗽”等范畴。发病年龄多见于6个月至6岁的小儿,1至3岁的婴幼儿最为常见;临床特点是常年发作,症状较重,病程较长,缠绵难愈,严重影响小儿的身心健康和生长发育。据报道儿科门诊中70%的患儿为呼吸道感染,其中30%为反复呼吸道感染。中医学认为小儿反复呼吸道感染是在肺、脾、肾三脏虚损的基础上,感受外邪而致营卫失和,脏腑失调所致。肺、脾、肾三脏功能不足极为关键。本病其标在肺,其本在肾,责之于脾。且其关键不在邪多,而在正气不足。因小儿脏腑娇嫩,气血未足,脾胃虚弱,肾气不充,肌肤娇嫩又腠理疏松,神气怯弱,筋骨未坚,五脏六腑功能皆不足,造成外邪反复侵袭,而致本病。
临床上,治疗小儿反复呼吸道感染的西药主要有匹多莫得、转移因子、卡介苗素等,便疗效不佳,且应用疗程较长,价格昂贵,经济负担重;而转移因子和卡介苗素均需肌肉注射途径给药,增加了患儿的痛苦,令患儿难以接受。临床上常用的治疗本病的中成药有施保利通、黄芪精等,施保利通主要由侧柏叶、赝靛根,紫锥菊根、抗坏血酸等组成,侧柏叶有止咳喘疗效,赝靛根取其抗菌和免疫促进作用,紫锥菊根有免疫刺激作用减少发炎,帮助人体对抗细菌和病毒;黄芪精由黄芪组成,具有补血养气,固本止汗的功效,用于气虚血亏,表虚自汗等症。主要应用于成年人,但对小儿不适应,且治疗率低。
发明内容
本发明的目的在于提供一种治疗小儿反复呼吸道感染的药物,纯中药制剂,无毒副作用,治愈率高。
本发明是这样实现的:
治疗小儿反复呼吸道感染的药物,其特征在于制成有效成分的原料组成按重量配比为:黄芪9-15、白术9-15、茯苓9-15、防风9-15、苍术9-15、煅牡蛎10-18、大腹皮10-15和连翘6-12。
本发明药物能明显改善反复呼吸道感染患儿临床症状,激发患儿自身免疫系统,使IgA,IgG,IgM分泌增加,从而提高患儿机体体液免疫功能。改善患者的免疫力、减少发病次数,用药过程中未见任何不良反应,可长期服用,易于被儿童接受。
本发明具有如下临床效果:
1、组方药材选料讲究,符合并按照中国药典及药理配伍,炮制、配伍得当,配合科学合理;
2、纯中药制剂,无毒副作用,服用方便,且价格实惠;
3、治愈率高。经验证,本发明治愈率达85%,总有效率93%。
本发明不仅强调抗感染、调节免疫方面的功效,还强调“脾胃为后天之本”,通过改善消化道内环境,提升先天性及适应性免疫,疗效更全面,虚实兼顾,更好地体现了“整体观念”及“辨证论治”在临床中的应用。
现代医学研究认为小儿反复呼吸道感染的发生主要是由于病毒、细菌、支原体等病原微生物侵入机体,造成呼吸道感染。此外,还与患儿的免疫系统功能发育不完善,体内代谢酶活性降低,环境因素及机体部分维生素缺乏等有关。中医学认为,治疗小儿反复呼吸道感染,应取补肺固表、健脾益胃、清除余邪之法,方能切中病机。明·万全早已提出小儿具有“脾常不足”、“肾常虚”、“娇肺遭伤不易愈”的生理病理特点。小儿五脏六腑功能皆属不足,尤其以肺、脾、肾三脏为突出。小儿脾常不足,若护理失宜,乳食失节,可致脾胃虚弱,纳运失常,气血生化乏源,土不生金,肺气亦虚,卫外功能薄弱,易受外邪侵袭。故治疗本病主要旨在扶正,增强机体自身免疫,兼清余邪。
本发明参考祖国医学对小儿反复呼吸道感染病因及病机的认识以及治疗的宝贵经验,参阅已有合理组方,辨证论治,按照祖国药典及药理配伍,推陈出新,是为传统医学治疗小儿反复呼吸道感染的成功药物,可有效治疗小儿反复呼吸道感染,并见食欲不振,湿热内积,自汗,盗汗,多汗者。
现代药理研究证明:
1、黄芪
性味,甘,微温,作用和缓,主要药理作用是益气固表,具有补而不腻的特点。黄芪含有多糖、甙、黄酮和微量元素等多种成分,对细胞代谢、核酸代谢、细菌及病毒感染等有显著作用,对免疫系统、内分泌系统等均有广泛的影响。
2、白术
性温,味甘、苦,具有补气健脾,燥湿健脾功效,可用于治脾胃气弱、汗出。化学成分主要为挥发油和多糖,还含有谷氨酸等多种氨基酸以及树脂、白术三醇、维生素A等物质。可以提高免疫细胞的数量,增强机体免疫功能。还有抗菌作用。
3、防风
性辛、甘、微温,有祛风解表、胜湿止痛、止痉作用。含有挥发油、升麻素、香豆素类、多糖类、脱糖素、酚类等,有抗菌、抗病毒,解热镇静,抗炎,促进提高免疫功能。
4、茯苓
味甘、淡平。有利水渗湿、健脾的功效。含β-茯苓聚糖,多种四环三萜类化合物,麦角甾醇、胆碱、腺嘌呤等。有调节免疫、抗感染、镇静、保肝等作用,临床用于痰饮眩悸、脾虚食少等证的治疗。
5、苍术
性辛、苦、温。具有燥湿健脾,祛风,散寒等功能。含挥发油,主要成分为苍术醇、苍术酮、茅术醇、榄香醇、多糖等。有抗炎、抑菌消毒、中枢神经系统抑制等作用。
6、煅牡蛎
性咸、微寒,有重镇安神、潜阳补阴、收敛固涩功效。主要成分有碳酸钙、微量元素和氨基酸。其具有抗病毒、抗氧化、镇静、抗惊厥等作用。
7、大腹皮
味辛,性微温,具有下气宽中之效,含槟榔碱及槟榔次碱等,有兴奋胃肠道平滑肌、促胃肠动力,并有促进纤维蛋白水解等作用。
8、连翘
性苦、微寒,有清热解毒,疏散风热等功效。主要含苯乙醇苷类、木脂体及其苷类、五环三萜类、挥发油类等化合物,有广谱抗病原微生物,抗炎,镇吐,抗肝损伤等作用。
中医理论认为,反复呼吸道感染的病机本质正是肺、脾、肾三脏虚损,而致卫外不固,反复感邪,病性多为本虚标实,其发病关键不在邪多,而在正气不足。病程可分为感染期、迁延期、恢复期。( 1) 急性期以邪实为主,初期多有外感表证,发热、咳嗽、鼻塞、流涕、喷嚏,甚至喘息、痰鸣、鼻煽; ( 2) 迁延期正虚邪恋,邪毒渐平,虚象尽露,热、痰、积未尽,肺脾肾虚显露,残留咳嗽、低热、多汗、烦躁、纳呆、肢倦等; ( 3) 恢复期正虚为主,需辨明何脏虚损。故本制剂以黄芪为君药,取其补气升阳,益卫固表之效,防风、白术、茯苓、苍术均为臣药,白术健脾益气,二药相须为用,固表之力尤著,使气旺表实,则一可止汗,二可御风。防风入脾而走表,既可协脾中清阳达表以实卫,又疏散风邪,与黄芪、白术相配,补中寓散,使固表不留邪,祛邪不伤正。三药合用,共奏益气固表,止汗御风之功。茯苓、白术、苍术合用增强健脾利湿功效,“培土生金”,脾旺则肺气足。煅牡蛎、大腹皮、连翘均为佐药,反复呼吸道感染患儿,体质多虚,自汗、盗汗、多汗症多见,此用煅牡蛎主要取其收敛止汗之效,且患儿多食欲欠佳,积滞于中,予大腹皮下气宽中,连翘清热解毒,祛邪外出,共同发挥益气固表,健脾和胃,祛邪外出功效。
具体实施方式
下面结合实施例对本发明作详细说明。
实施例1
(1)取方中药物黄芪15g、白术10g、茯苓10g、防风9g、苍术10g、煅牡蛎12g、大腹皮10g和连翘6g。加水浸泡半小时,加热蒸煮1.5小时,取过滤液待用。
(2)蒸煮后残渣再加水蒸煮1小时,得过滤液。
(3)合并2次得滤液,即得本发明药物。口服:每日3次,每日5-20ml。
使用方法:本发明可制备成口服液剂型,还可以按常规方法制备成散剂、丸剂、冲剂、胶囊和膏剂,也可以取上述原料药按配比作重要煎剂服用。
实施例2
分取黄芪15g、白术15g、茯苓15g、防风15g、苍术15g、煅牡蛎18g、大腹皮15g和连翘12g。制作方法及服用方法同实施例1,可有效治疗小儿反复呼吸道感染,兼食欲不振,食积,汗多者。
实施例3
分取黄芪12g、白术12g、茯苓10g、防风10g、苍术10g、煅牡蛎15g、大腹皮12g和连翘10g。制作方法及服用方法同实施例1,可有效治疗小儿反复呼吸道感染,兼热毒侵袭,汗多者。
临床试验
为验证本发明药物的疗效,申请人于2010-2013年在山东省聊城市人民医院儿科进行如下临床试验:
一、临床资料
共试验小儿反复呼吸道感染患者243例,其中女94例,男149例,年龄介于6月-6岁之间。
将上述患者随机分为两组:
第一组为治疗组,共131例,其中女48例,男83例;
第二组为对照组,共112例,其中女46例,男66例。
二、诊断标准
参照1987年全国第一届RRTI呼吸道疾病学术会议制定的RRTI诊断标准[1]。每年上呼吸道感染次数分别为0-2岁≥7次,3-5岁≥6次,6-12岁≥5次。每年下呼吸道感染次数分别为0-2岁≥3次,3-5岁≥2次,6-12岁≥2次。上呼吸道感染第2次距第1次至少7 d以上。若上感次数未达到标准,可加下呼吸道感染次数,反之则不成立,至少观察1年。
三、治疗方法
治疗组:口服本发明药物水煎剂,每日一剂,分二次服用。
对照组:口服匹多莫得 0.4g,每日1次。
四、疗效评价标准
根据1987年全国小儿呼吸道疾病会议制定的疗效标准拟订。
痊愈:治疗后6个月内没有再发生呼吸道感染;
显效:治疗后3个月内没有再发生呼吸道感染;
有效:治疗后1个月内没有再发生呼吸道感染;
无效:治疗后1个月内仍有呼吸道感染发生,且呼吸道感染次数没有减少。
五、疗效
统计学方法:运用SPSS17.0统计软件统计数据,对计量数据的统计,以均数、标准差表示,必要时加用中位数或百分位数、最小值、最大值表示,对变量分布进行正态检验,服从正态分布时,用t检验,方差不齐者,用t’检验;非正态分布,用秩和检验等;对计数数据,采用fisher精确概率法或X2检验;等级数据的自身前后比较用Wilcoxon符号秩和检验;两组等级数据的比较用Ridit分析,或相应的秩和检验。所有统计计算均用统计软件进行,以P≤0.5作为有显著性统计学意义,以P≤0.01作为有非常显著性统计学意义。
疗效结果见下表:
两组总有效率比较,P<0.05,差异显著。
六、结论
通过实验研究发现,本方能通过抗炎、抗病原体,能有效的预防风寒刺激导致巨噬细胞吞噬和杀菌功能的抑制,且预防抑制淋巴细胞的免疫功能,具有良好的免疫调节作用。另外,中医理论强调“脾胃为后天之本”,本方通过改善胃肠道功能,改善消化道内在环境,抵抗其它菌株的移植,调节粘膜免疫系统,调节呼吸道粘膜,提升先天性免疫及适应性免疫。
治疗组痊愈率、总有效率明显优于对照组。
七、具体病例
病例1,李某,男,4岁。
自2岁后反复发作上呼吸道感染,2年来发作30余次。表现为咳嗽、发热、鼻塞、喷嚏、流涕、精神不佳、进食减少等。查体:咽红充血,扁桃体Ⅱ度肿大,呈陈旧性增生,每次发作时体温升高,一般在38~40 ℃。每次予抗感染、退热等对症治疗,但易反复,平时体质差。诊断为小儿反复呼吸道感染。给予本发明药物,水煎服用,服药2周后,患儿出汗减少,食欲较前改善,1月后,精神反应较前明显好转,饮食量较前明显增加,随访1年,患儿感冒次数较前明显减少,且感冒时嘱予对症治疗,病程缩短。
病例2,男,3岁
平素体弱,易感冒,纳少,既往有7-8次气喘病史,每次发作都要住院10天不等,1岁半时确诊为支气管哮喘,一直予普米克吸入。其爷爷有哮喘史。此次因“咳嗽、流鼻涕3天,气喘2天”就诊。患儿3天前无明显诱因出现流鼻涕,咳嗽,2天前出现气喘,活动后加重,无发热,无呕吐、腹泻,饮食减少,大小便基本正常,入院查体:精神欠佳,鼻翼稍煽动,咽充血,扁桃体II°肿大,三凹征阳性,听诊双肺呼吸音粗,可闻及显著喘鸣音,呼气相延长。予抗病毒、祛痰止咳、抗炎平喘等综合治疗,治疗12天好转出院后,嘱其口服本制剂,1个月后随访,食欲增强,体重增加,2个月后随访,感冒次数减少,体格较前健壮,5个月后随访,气喘次数减少,易感冒情况明显改善。
Claims (2)
1.治疗小儿反复呼吸道感染的药物,其特征在于制成有效成分的原料组成按重量配比为:黄芪9-15、白术9-15、茯苓9-15、防风9-15、苍术9-15、煅牡蛎10-18、大腹皮10-15和连翘6-12。
2.根据权利要求1所述的治疗小儿反复呼吸道感染的药物,其特征在于其中制成有效成分的原料组成及重量配比为:黄芪15、白术10、茯苓10、防风9、苍术10、煅牡蛎12、大腹皮10和连翘6。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410114442.9A CN103830481B (zh) | 2014-03-26 | 2014-03-26 | 治疗小儿反复呼吸道感染的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410114442.9A CN103830481B (zh) | 2014-03-26 | 2014-03-26 | 治疗小儿反复呼吸道感染的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103830481A true CN103830481A (zh) | 2014-06-04 |
CN103830481B CN103830481B (zh) | 2016-08-17 |
Family
ID=50794583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410114442.9A Active CN103830481B (zh) | 2014-03-26 | 2014-03-26 | 治疗小儿反复呼吸道感染的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103830481B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107281418A (zh) * | 2017-06-21 | 2017-10-24 | 成都中医药大学 | 一种食品、功能食品或药物组合物及其制备方法和用途 |
CN107714743A (zh) * | 2017-11-30 | 2018-02-23 | 王博 | 一种用于治疗小儿反复呼吸道感染的药物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1544040A (zh) * | 2003-11-21 | 2004-11-10 | 广州康和药业有限公司 | 增强儿童免疫能力的药物及其制备方法 |
CN1903334A (zh) * | 2006-07-28 | 2007-01-31 | 解备卿 | 预防小儿反复呼吸道感染和治疗消化不良的中成药制剂 |
-
2014
- 2014-03-26 CN CN201410114442.9A patent/CN103830481B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1544040A (zh) * | 2003-11-21 | 2004-11-10 | 广州康和药业有限公司 | 增强儿童免疫能力的药物及其制备方法 |
CN1903334A (zh) * | 2006-07-28 | 2007-01-31 | 解备卿 | 预防小儿反复呼吸道感染和治疗消化不良的中成药制剂 |
Non-Patent Citations (1)
Title |
---|
邱文英: "小儿反复呼吸道感染的中药治疗", 《江西中医药》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107281418A (zh) * | 2017-06-21 | 2017-10-24 | 成都中医药大学 | 一种食品、功能食品或药物组合物及其制备方法和用途 |
CN107281418B (zh) * | 2017-06-21 | 2021-01-15 | 成都中医药大学 | 一种药物组合物及其制备方法和用途 |
CN107714743A (zh) * | 2017-11-30 | 2018-02-23 | 王博 | 一种用于治疗小儿反复呼吸道感染的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103830481B (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091282B (zh) | 一种治疗慢性胃炎、胃溃疡的药物 | |
CN102772778A (zh) | 一种治疗暑湿感冒的中药组合物 | |
CN102357133A (zh) | 治疗变应性鼻炎的中药代茶冲泡饮剂 | |
CN101766787B (zh) | 治疗高热、咳喘的灌肠液 | |
CN101884779A (zh) | 一种用于干预亚健康状态的黄精组合物及其制备方法 | |
CN102091307B (zh) | 一种治疗感冒的中药组合物 | |
CN104288624A (zh) | 药物组合物及其用途 | |
CN103830481B (zh) | 治疗小儿反复呼吸道感染的药物 | |
CN105381153A (zh) | 治疗支气管炎的中药制剂及制备方法 | |
CN104147194A (zh) | 一种治疗慢性鼻窦炎的中药组合物 | |
CN101601822A (zh) | 一种治疗小儿咳嗽喉鸣的药物及其制备方法 | |
CN106138279A (zh) | 治疗鼻炎的药物组合物及其制备方法 | |
CN104367975A (zh) | 一种止咳祛痰款冬花膏 | |
CN104173737A (zh) | 一种治疗肺间质纤维化的中药配方 | |
CN103536673B (zh) | 兼具强力增强免疫力的消积退热止咳喘外用散及其应用 | |
CN106389738A (zh) | 一种治疗便秘的中药冲剂 | |
CN105999196A (zh) | 一种用于治疗急性腹膜炎的中药制剂及制备方法 | |
CN105213627A (zh) | 一种用于治疗太阳表虚的中药 | |
CN103446370B (zh) | 一种治疗脾虚痰湿型痤疮的中药组合物 | |
CN104127504B (zh) | 小儿感冒咳嗽糖浆及其制备方法 | |
CN105055844A (zh) | 一种治疗慢性便秘的中药制剂 | |
CN105194545B (zh) | 一种治疗哮喘的中药组合物 | |
CN105168847A (zh) | 一种用于治疗幽门螺杆菌感染性消化性溃疡的中药 | |
CN104042872A (zh) | 治疗小儿感冒的中药组合物及其制备方法 | |
CN104524094A (zh) | 一种治疗梅核气的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |